2019
Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry
Faridi KF, Rymer JA, Rao SV, Dai D, Wojdyla D, Yeh RW, Wang TY. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. American Heart Journal 2019, 216: 53-61. PMID: 31401443, DOI: 10.1016/j.ahj.2019.07.004.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleHeart FailureHumansLogistic ModelsMaleOdds RatioPercutaneous Coronary InterventionPeripheral Vascular DiseasesPostoperative ComplicationsPostoperative HemorrhageRegistriesRenal Insufficiency, ChronicTreatment OutcomeConceptsStable coronary artery diseaseRisk of AKIPercutaneous coronary interventionAcute kidney injuryCoronary artery diseaseNational Cardiovascular Data Registry CathPCI RegistryCathPCI RegistryCoronary interventionArtery diseaseMultivessel percutaneous coronary interventionCoronary artery bypass graftDiagnostic coronary angiographyArtery bypass graftChronic kidney diseasePeripheral vascular diseaseGlomerular filtration rateChronic total occlusionAKI riskHospital bleedingPCI useKidney injuryCoronary angiographyHeart failureBypass graftUS patients
2018
Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval
Faridi KF, Popma JJ, Strom JB, Shen C, Choi E, Yeh RW. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. The American Journal Of Cardiology 2018, 121: 1365-1372. PMID: 29627105, DOI: 10.1016/j.amjcard.2018.02.016.Peer-Reviewed Original ResearchConceptsPercutaneous mitral valve repairMitral valve repairValve repairHospital volumeClinical comorbiditiesReduced hospital readmissionsHospital mortality rateDays of dischargeIn-Hospital MortalityNationwide Readmissions DatabaseAdministrative claims databaseHospital readmission ratesRoutine clinical practiceDevice approvalCause mortalityHospital deathMultivariable adjustmentPatient demographicsReadmission ratesHospital readmissionMitraClip deviceClaims databaseHospital characteristicsRisk factorsProcedural volume
2016
Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices
Houston BA, Schneider AL, Vaishnav J, Cromwell DM, Miller PE, Faridi KF, Shah A, Sciortino C, Whitman G, Tedford RJ, Stevens GR, Judge DP, Russell SD, Rouf R. Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. The Journal Of Heart And Lung Transplantation 2016, 36: 380-385. PMID: 28169115, DOI: 10.1016/j.healun.2016.12.016.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceGastrointestinal bleedingAngiotensin II antagonismARB therapyVascular endothelial growth factorArteriovenous malformationsVentricular assist deviceAssist deviceAngiotensin receptor blocker therapyContinuous-flow Left Ventricular Assist DevicesAssociation of ACEIReceptor blocker therapyInternational normalized ratioRegression hazard modelGastrointestinal arteriovenous malformationsJohns Hopkins HospitalLogistic regression analysisRisk of AVMAngiotensin II SignalingEndothelial growth factorBlocker therapyRenal functionAdult patientsBlood pressureCardiomyopathy etiology